Drug intelligence / Profile preview

metaproterenol + theophylline

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Inhalation

Overview

A combination bronchodilator medication containing metaproterenol and theophylline used to treat chronic airflow obstruction (CAO), asthma, and other lung diseases. Metaproterenol provides rapid bronchodilation while theophylline offers sustained bronchodilator effects. The combination works by relaxing the smooth muscles in the bronchial tubes and increasing airflow through the lungs.

Targets

ADOR (Adenosine receptors)PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on metaproterenol + theophylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on metaproterenol + theophylline.

Explore the full profile